1207455-37-5

Basic information

• Product Name: 4-benzyl 1-tert-butyl 2,6-dimethylpiperazine-1,4-dicarboxylate
• Synonyms: 4-benzyl 1-tert-butyl 2,6-dimethylpiperazine-1,4-dicarboxylate
• CAS NO: 1207455-37-5
• Molecular Weight: 348.442
• Mol File: 1207455-37-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-benzyl 1-tert-butyl 2,6-dimethylpiperazine-1,4-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 4-benzyl 1-tert-butyl 2,6-dimethylpiperazine-1,4-dicarboxylate(1207455-37-5)
• EPA Substance Registry System: 4-benzyl 1-tert-butyl 2,6-dimethylpiperazine-1,4-dicarboxylate(1207455-37-5)

Safety Data

• Hazardous Substances Data: 1207455-37-5(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 501-53-1 benzyl chloroformate 
• 108-49-6 3,5-dimethylpiperazine 
• 885278-83-1 benzyl 3,5-dimethylpiperazine-1-carboxylate 

Downstream Products

• 885278-83-1 benzyl 3,5-dimethylpiperazine-1-carboxylate 
• 1207455-38-6 (2R,6R)-tert-butyl 4-(4-(9-(4-fluorophenyl)-3-oxo-3,7,8,9-tetrahydro-2H-pyrido[4,3,2-de]phthalazin-8-yl)benzyl)-2,6-dimethylpiperazine-1-carboxylate 
• 1207455-36-4 8-(4-((3,5-dimethylpiperazin-1-yl)methyl)phenyl)-9-(4-fluorophenyl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one 
• 574007-62-8 tert-butyl 2,6-dimethylpiperazine-1-carboxylate 

Relevant articles and documents

Design, synthesis and SAR of antitubercular benzylpiperazine ureas

Abstract: N-furfuryl piperazine ureas disclosed by scientists at GSK Tres Cantos were chosen as antimycobacterial hits from a phenotypic whole-cell screen. Bioisosteric replacement of the furan ring in the GSK Tres Cantos molecules with a phenyl ring led to molecule (I) with an MIC of 1?μM against Mtb H37Rv, low cellular toxicity (HepG2 IC50 ~ 80?μM), good DMPK properties and specificity for Mtb. With the aim of delineating the SAR associated with (I), fifty-five analogs were synthesized and screened against Mtb. The SAR suggests that the piperazine ring, benzyl urea and piperonyl moieties are essential signatures of this series. Active compounds in this series are metabolically stable, have low cellular toxicity and are valuable leads for optimization. Molecular docking suggests these molecules occupy the Q0 site of QcrB like Q203. Graphic Abstract: Bioisosteric replacement of N-furfuryl piperazine-1-carboxamides yielded molecule (I) a novel lead with satisfactory PD, metabolism, and toxicity profiles.[Figure not available: see fulltext.]

METHODS OF USING DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY (ADP-RIBOSE)POLYMERASE (PARP)

Provided herein are methods of treating cancer comprising administering a topoisomerase inhibitor, temozolomide, or a platin in combination with a Compound of Formula (I) or Formula (II), where the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein.